James McGuire, DPM
Podiatrist · Philadelphia, PANPI 1942295829
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.3%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Smith+Nephew at 46.4% of the total. Reporting peaked in 2019 at $22,887 and has fallen 96.4% since, to $833 in 2025. Among podiatrist clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 182 payments — averaging $331.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$28K
- Reapplix Inc.$14K
- Bsn Medical Inc$13K
- Musculoskeletal Transplant Foundation Inc.$2K
- Osiris Therapeutics Inc.$2K
- Kerecis Limited$695
- plus $1K from 26 others
What the payments were for
- Consulting fees$17,80430%
- Speaking & faculty fees$33,36855%
- Travel & lodging$3,8816%
- Food & beverage$5,2459%
- Education$350%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 104 | $28,016 |
| Reapplix Inc. | 12 | $14,237 |
| Bsn Medical Inc | 9 | $12,512 |
| Musculoskeletal Transplant Foundation Inc. | 3 | $1,850 |
| Osiris Therapeutics Inc. | 4 | $1,646 |
| Kerecis Limited | 9 | $695 |
| Paratek Pharmaceuticals, Inc. | 4 | $167 |
| Zimmer Biomet | 1 | $165 |
| Medline Industries LP | 1 | $149 |
| Tactile Systems Technology Inc | 2 | $145 |
| AstraZeneca | 4 | $91 |
| Organogenesis Inc. | 4 | $81 |
| LEO Pharma Inc. | 1 | $63 |
| Averitas Pharma Inc. | 2 | $53 |
| Bristol Myers Squibb | 2 | $45 |
| Sebela Pharmaceuticals Inc. | 2 | $44 |
| Nevro Corp. | 2 | $37 |
| Medtronic | 1 | $35 |
| Integra Lifesciences Corporation | 2 | $34 |
| Solventum Corporation | 1 | $31 |
| Hartmann USA, Inc. | 1 | $25 |
| Lifenet Health | 1 | $24 |
| Vertex | 1 | $23 |
| Polarityte, Inc. | 1 | $22 |
| BTG International Inc. | 1 | $22 |
| KCI USA, Inc. | 1 | $21 |
| Hydrofera LLC | 1 | $21 |
| Melinta Therapeutics, LLC | 1 | $19 |
| Mimedx Group, Inc. | 1 | $17 |
| Polynovo North America LLC | 1 | $15 |
| Misonix Inc | 1 | $14 |
| Convatec Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Santyl$11,621
- COLLAGENASE SANTYL$11,078
- 3C Patch Kit - Box$10,629
- REGRANEX$5,155
- Oasis$4,076
- CUTIMED SORBACT$3,091
- 3C Patch Kit$2,000
- Stravix$1,882
- Grafix$1,746
- GrafixPL$1,746
- 3C PATCH$1,500
- VERSAJET II$1,400
- Kerecis SurgiClose$1,126
- Kerecis Omega3 SurgiClose$412
- GRAFIX PL$395
- Kerecis GraftGuide$281
- Hyalomatrix Wound Device$149
- Kerecis Omega3 GraftGuide$137
- Kerecis Omega3 Marigen$137
- STRAVIX MESH$136
How this compares
$60,332 in reported general payments places this provider in the 95th percentile of 445 podiatrist providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SantylCollagenase Clostridium Hist. | 29 | $25,913 |
| Ciclopirox | 105 | $2,487 |
| Ammonium Lactate | 163 | $2,486 |
| Clindamycin Phosphate | 46 | $1,760 |
| Clobetasol Propionate | 23 | $1,622 |
| CiclopiroxCiclopirox Olamine | 120 | $1,506 |
| Ketoconazole | 77 | $1,385 |
| Mupirocin | 130 | $823 |
| Diclofenac Sodium | 26 | $732 |
| Doxycycline Hyclate | 59 | $656 |
| Methylprednisolone | 40 | $368 |
| Celecoxib | 15 | $280 |
| Terbinafine Hcl | 19 | $208 |
| Triamcinolone Acetonide | 11 | $89 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 11 | $84 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Smith+NephewSantyl | $28,016 | $25,91329 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 445 podiatrist providers in Pennsylvania.
Other podiatrist in Philadelphia
- Daniel PerezPhiladelphia$434K
- Kwasi KwaaduPhiladelphia$65K
- Luke CicchinelliPhiladelphia$62K
- Richard JayPhiladelphia$10K
- Elena WellensPhiladelphia$8K
- Kieran MahanPhiladelphia$6K
- Ashmi ShahPhiladelphia$6K
- Mark HofbauerBelle Vernon$1.1M
- Christopher BarrettChester$229K
- Alan CatanzaritiPittsburgh$80K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.